Thus, PLD1 inhibition linked to the upregulation of ICAT might increase the treatment sensitivity of CRC cells with hyperactivation of the Wnt/β-catenin and PI3K/Akt signaling pathways (Fig. 2b). The gene discussed is AKT1; the disease is colorectal carcinoma.